iX Biopharma Ltd. (SGX: 42C)
Singapore flag Singapore · Delayed Price · Currency is SGD
0.0230
0.00 (0.00%)
Dec 18, 2024, 9:00 AM SGT

iX Biopharma Ratios and Metrics

Millions SGD. Fiscal year is Jul - Jun.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '24 Jun '24 Jun '23 Jun '22 Jun '21 Jun '20 2019 - 2015
Market Capitalization
202270122167162
Upgrade
Market Cap Growth
-68.05%-68.05%-43.05%-26.84%3.17%-1.31%
Upgrade
Enterprise Value
242262111162156
Upgrade
PS Ratio
3.743.7411.798.5195.91164.69
Upgrade
PB Ratio
5.135.134.406.2014.2915.95
Upgrade
P/TBV Ratio
5.515.514.486.3114.8116.69
Upgrade
P/FCF Ratio
---41.89--
Upgrade
P/OCF Ratio
---39.21--
Upgrade
EV/Sales Ratio
3.973.7310.517.7092.74157.93
Upgrade
EV/EBITDA Ratio
---96.40--
Upgrade
EV/EBIT Ratio
---221.09--
Upgrade
EV/FCF Ratio
-3.47--37.89--
Upgrade
Debt / Equity Ratio
1.201.200.270.220.360.39
Upgrade
Debt / EBITDA Ratio
---2.91--
Upgrade
Debt / FCF Ratio
---1.51--
Upgrade
Asset Turnover
0.300.300.220.610.100.05
Upgrade
Inventory Turnover
4.204.203.862.092.141.81
Upgrade
Quick Ratio
0.650.651.341.982.192.14
Upgrade
Current Ratio
0.890.891.532.142.552.47
Upgrade
Return on Equity (ROE)
-106.91%-106.91%-54.02%-29.24%-75.27%-68.47%
Upgrade
Return on Assets (ROA)
-23.69%-23.69%-22.32%1.32%-39.86%-31.95%
Upgrade
Return on Capital (ROIC)
-31.51%-31.51%-26.91%1.56%-47.57%-36.32%
Upgrade
Earnings Yield
-48.44%-48.44%-13.79%-3.76%-4.92%-6.47%
Upgrade
FCF Yield
-30.64%-30.64%-11.98%2.39%-5.32%-5.74%
Upgrade
Buyback Yield / Dilution
-0.33%-0.33%-2.51%-7.60%-7.13%-0.54%
Upgrade
Total Shareholder Return
-0.33%-0.33%-2.51%-7.60%-7.13%-0.54%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.